Effects of pimobendan on prolonging time to rehospitalization or frequency of readmission in patients with heart failure.-a retrospective cohort study using medical administrative database-(PREFER study)

Not Applicable

• Conditions: Heart Failure

• Registration Number: JPRN-UMIN000034228
• Lead Sponsor: Saiseikai Kumamoto Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-10-01
• Study Completion: 2019-02-22
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients whom had discharge JCS score was more than 1 at the hospitalization at the start of follow-up period. 2.Patients whom had discharge ADL score was less than 12 at the hospitalization at the start of follow-up period. 3.Patients who received pimobendan short term prescription. 4.Patients who have prescribed Vesnarinone,Denopamine,Docarpamine,during the follow-up period. 5.Patients who are prescribed inotropic injections(Dopamine hydrochloride,Dobutamine hydrochloride,PDE3inhibitors or Colforsin daropate hydrochloride) at the outpatient visits during the follow-up period. 6.Patients who had the following records within 90 days prior to the start of the follow-up period: -Cardiac surgery(CABG,Valvuloplasty,Valve replacement surgery,etc.)(category code; K522,K554,K555,K5763,K5792,Including combined operation cases.) -TAVI(category code;K555-02) -Cardiac resynchronization therapy(CRT)(category code;K598,K598-02,K599-03,K599-04) -PCI(category code;K546,K547,K548,K549,K550) 7.Patient who have the following diagnosis or procedures within the study target period:Malignant tumor(ICD10;C00-C97) -Heart transplantation(category code;K605-02) -Left Ventricular Assist Device(LVAD)(category code;C116,K603,K6042,K604-02)

Study & Design

• Study Type: Observational
• Study Design: Not specified